Dogwood Therapeutics
Dogwood Therapeutics

Dogwood Therapeutics

Pharmaceuticals
WebsiteInvestor RelationsSEC
Dogwood Therapeutics Inc, formerly Virios Therapeutics Inc, is a development-stage biotechnology company. It is focused on advancing novel antiviral therapies to treat diseases associated with a virus-triggered abnormal immune response, such as fibromyalgia (FM) and long COVID (LC). Its product candidates include IMC-1 and IMC-2. IMC-1 is intended to synergistically suppress herpesvirus activation and replication with a more specific activity against the Epstein-Barr virus (herpesvirus HHV-4, IMC-2 is a combination of valacyclovir and celecoxib.

$49.6M

Market Cap • 10/2/2026

2020

(6 years)

Founded

2020

(6 years ago)

IPO

NASDAQ

Listing Exchange

Flag of United States

United States

Country

Valuation

P/B

0,7

P/S

—

P/EBITDA

—

P/OCF

—

P/FCF

—

P/E

—

BVPS

2

EPS

—

Market Cap

Market Cap

49,6M

EV

40,1M

EV/Revenue

0

EV/EBITDA

-1

EV/EBIT

-1

Payout

Dividend Per Share

0

Dividend Yield

0%

Buyback Yield

-23%

Total Yield

-23%

Payout

0%

Retained Earnings

-124,6M

Profitability

Gross Margin

—

EBITDA Margin

—

EBIT Margin

—

Net Margin

—

D&A/EBITDA

0%

R&D/Revenue

0%

Capex/Revenue

0%

Capex/D&A

0%

Capex/OCF

0%

SBC/OCF

—

% PPE

0,2%

% Goodwill

14,9%

ROE

—

ROIC

—

Growth

CAGR Op. Income 5Y

18,7%

CAGR Net Income 5Y

16,8%

CAGR EPS 5Y

-33,2%

CAGR OCF 5Y

7,1%

Leverage

N.D./EBITDA

0,2

Debt/Equity

0%

Current Ratio

3,9

Quick Ratio

3,4

Interest Coverage

—

Premium

Unlock 100% of the data and have immediate access on more than 6.000 companies with updated information!
  • Unrestricted access
  • Unlimited data history
  • Analysis videos
  • Quarterly highlights
  • Customizable financials table
  • Ranking
  • Discussions

...and much more!

Get Premium